Literature DB >> 28581461

Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma.

L Giaccone1,2, M Festuccia3, F Zallio4, R Sorasio5, L Brunello2,3, E Maffini1,2, C Dellacasa1, R Passera6, G Iovino7, S Aydin7, M Boccadoro2,3, U Vitolo7, N Mordini5, M Pini4, A Busca1, B Bruno1,2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28581461     DOI： 10.1038/bmt.2017.99

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  23 in total

1.  Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.

Authors:  Karl S Peggs; Ann Hunter; Rajesh Chopra; Anne Parker; Premini Mahendra; Donald Milligan; Charles Craddock; Ruth Pettengell; Ahmet Dogan; Kirsty J Thomson; Emma C Morris; Geoff Hale; Herman Waldmann; Anthony H Goldstone; David C Linch; Stephen Mackinnon
Journal:  Lancet       Date:  2005 Jun 4-10       Impact factor: 79.321

2.  Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation.

Authors:  Miguel-Angel Perales; Izaskun Ceberio; Philippe Armand; Linda J Burns; Robert Chen; Peter D Cole; Andrew M Evens; Ginna G Laport; Craig H Moskowitz; Uday Popat; Nishitha M Reddy; Thomas C Shea; Julie M Vose; Jeffrey Schriber; Bipin N Savani; Paul A Carpenter
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-12       Impact factor: 5.742

Review 3.  Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.

Authors:  A Sureda; P Bader; S Cesaro; P Dreger; R F Duarte; C Dufour; J H F Falkenburg; D Farge-Bancel; A Gennery; N Kröger; F Lanza; J C Marsh; A Nagler; C Peters; A Velardi; M Mohty; A Madrigal
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

4.  Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.

Authors:  Achim Rothe; Stephanie Sasse; Helen Goergen; Dennis A Eichenauer; Andreas Lohri; Ulrich Jäger; Christopher Bangard; Boris Böll; Michael von Bergwelt Baildon; Sebastian Theurich; Peter Borchmann; Andreas Engert
Journal:  Blood       Date:  2012-07-11       Impact factor: 22.113

Review 5.  Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning.

Authors:  Frédéric Baron; Marie-Térèse Little; Rainer Storb
Journal:  Blood Rev       Date:  2005-05       Impact factor: 8.250

6.  Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation.

Authors:  P Tsirigotis; I Danylesko; K Gkirkas; N Shem-Tov; R Yerushalmi; M Stamouli; A Avigdor; A Spyridonidis; J Gauthier; G Goldstein; J Apostolidis; M Mohty; A Shimoni; A Nagler
Journal:  Bone Marrow Transplant       Date:  2016-05-16       Impact factor: 5.483

7.  Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.

Authors:  Lauri M Burroughs; Paul V O'Donnell; Brenda M Sandmaier; Barry E Storer; Leo Luznik; Heather J Symons; Richard J Jones; Richard F Ambinder; Michael B Maris; Karl G Blume; Dietger W Niederwieser; Benedetto Bruno; Richard T Maziarz; Michael A Pulsipher; Finn B Petersen; Rainer Storb; Ephraim J Fuchs; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

8.  Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.

Authors:  Paolo Anderlini; Rima Saliba; Sandra Acholonu; Sergio A Giralt; Borje Andersson; Naoto T Ueno; Chitra Hosing; Issa F Khouri; Daniel Couriel; Marcos de Lima; Muzaffar H Qazilbash; Barbara Pro; Jorge Romaguera; Luis Fayad; Frederick Hagemeister; Anas Younes; Mark F Munsell; Richard E Champlin
Journal:  Haematologica       Date:  2008-01-26       Impact factor: 9.941

9.  Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials.

Authors:  Pier Luigi Zinzani; Simonetta Viviani; Antonella Anastasia; Umberto Vitolo; Stefano Luminari; Francesco Zaja; Paolo Corradini; Michele Spina; Ercole Brusamolino; Alessandro M Gianni; Armando Santoro; Barbara Botto; Enrico Derenzini; Cinzia Pellegrini; Lisa Argnani
Journal:  Haematologica       Date:  2013-05-03       Impact factor: 9.941

10.  Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma.

Authors:  A Raiola; A Dominietto; R Varaldo; A Ghiso; F Galaverna; S Bramanti; E Todisco; B Sarina; L Giordano; A Ibatici; A Santoro; M Clavio; A Bacigalupo; L Castagna
Journal:  Bone Marrow Transplant       Date:  2013-11-04       Impact factor: 5.483
View more
  3 in total

Review 1.  Fertility preservation in Hodgkin's lymphoma patients that undergo targeted molecular therapies: an important step forward from the chemotherapy era.

Authors:  Alexandra Traila; Patriciu Achimas-Cadariu; Delia Dima; Romeo Micu
Journal:  Cancer Manag Res       Date:  2018-06-13       Impact factor: 3.989

2.  Relapsing/refractory HL after autotransplantation: which treatment?

Authors:  Nicola Di Renzo; Francesco Gaudio; Carmelo Carlo Stella; Sara Oppi; Matteo Pelosini; Roberto Sorasio; Caterina Stelitano; Luigi Rigacci
Journal:  Acta Biomed       Date:  2020-05-25

Review 3.  The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma.

Authors:  Jeremy A Meier; Barbara Savoldo; Natalie S Grover
Journal:  J Pers Med       Date:  2022-02-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.